10/05/2026
The Board of Directors of NeoGenomics has appointed Warren Stone, current President and Chief Operating Officer (COO), as Chief Executive Officer (CEO) and a member of the Board, effective January 4, 2027.
Tony Zook, the Company's current CEO and a member of the Board, will transition to Executive Chair at that time and will continue to work in close alignment with Warren and the Board.
Warren's appointment reflects years of deliberate succession planning to ensure continuity of the executive team and a consistent growth strategy at NeoGenomics.
Tony, the leadership team, and Warren have worked closely to establish the strategy, capabilities, and foundation for NeoGenomics' next chapter.
Warren has more than three decades of Life Sciences and Diagnostics leadership experience, including senior leadership roles at Ortho Clinical Diagnostics and MilliporeSigma/Merck KGaA. Since joining NeoGenomics in 2022, he has held roles of increasing responsibility, including President of Clinical Services, Chief Commercial Officer, and most recently President & Chief Operating Officer, giving him a deep understanding of both the Company and its sector: https://ir.neogenomics.com/news-events/press-releases/detail/339/neogenomics-announces-executive-leadership-and-board-of-directors-succession-plan.
